What is DnaNudge?
Founded in 2015, DnaNudge is a British company at the forefront of personalized health solutions. The company specializes in DNA testing for critical health areas including hypertension, cholesterol, and type two diabetes research. Operating from the United Kingdom, DnaNudge leverages genetic insights to provide actionable health information, positioning itself as a key player in the health technology and diagnostics landscape.
How much funding has DnaNudge raised?
DnaNudge has raised a total of $60M across 1 funding round:
Series A
$60M
Series A (2021): $60M with participation from Ventura Capital and Bank Julius Baer
Key Investors in DnaNudge
Ventura Capital
Ventura Capital is an investment firm that likely focuses on providing capital for growth-stage companies.
Bank Julius Baer
Bank Julius Baer is a prominent private banking group, suggesting a strategic interest in supporting companies with significant growth potential.
What's next for DnaNudge?
The recent major strategic investment signifies a pivotal moment for DnaNudge, likely enabling the company to accelerate its research and development efforts, expand its testing capabilities, and broaden its market reach. This infusion of capital is expected to fuel further innovation in personalized medicine, particularly in the management and prevention of chronic conditions like hypertension and diabetes. The company's trajectory suggests a focus on scaling its operations and solidifying its position as a leader in genetic health diagnostics.
See full DnaNudge company page
